WO2023057946 - SERUM HALF-LIFE EXTENDED PD-L1 BINDING POLYPEPTIDES
National phase entry:
Publication Number
WO/2023/057946
Publication Date
13.04.2023
International Application No.
PCT/IB2022/059548
International Filing Date
06.10.2022
Title **
[English]
SERUM HALF-LIFE EXTENDED PD-L1 BINDING POLYPEPTIDES
[French]
POLYPEPTIDES SÉRIQUES DE LIAISON PD-L1 PROLONGÉS À DEMI-VIE
Applicants **
AVACTA LIFE SCIENCES LIMITED
Unit 20, Ash Way, Throp Arch Estate
Wetherby, Yorkshire LS23 7FA, GB
Inventors
BASRAN, Amrik
42 Beaumont Road
Cambridge, Cambridgeshire CB1 8PY, GB
JENKINS, Emma
47 Brook Road
Stansted, Essex CM24 8BB, GB
ADAM, Estelle
42b Bearton Road
Hitchin, Cambridgeshire SG5 1UE, GB
STANLEY, Emma
65 West Hill
Hitchin, SG5 2HY, GB
WRITER, Michele
32 Charles Street
Cambridge, Cambridgeshire CB1 3LZ, GB
Priority Data
63/253,446
07.10.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 5302 | |
| EPO | Filing, Examination | 32415 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 16210 |
Total: 55092 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure provides engineered PD-L1-binding Stefin A polypeptide variants, polynucleotides encoding the engineered PD-L1-binding Stefin A polypeptide variants, cells expressing the polypeptide variants, pharmaceutical preparations of the polypeptide variants, and uses of the polypeptide variants in the treatment of various human conditions, including cancer.[French]
La présente divulgation concerne des variants polypeptidiques modifiés de la stéfine A se liant à PD-L1, des polynucléotides codant pour ces variants polypeptidiques modifiés de la stéfine A se liant à PD-L1, des cellules exprimant lesdits variants polypeptidiques, des préparations pharmaceutiques desdits variants polypeptidiques et des utilisations desdits variants polypeptidiques dans le traitement de diverses affections humaines, notamment le cancer.